Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

Maxima Butterfly From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network

Coordinator
Prinses Maxima Centrum Voor Kinderoncologie BV, Netherlands
Runs
1 January 2023 to 31 December 2027
Status
Running
EU funding
€3.8m
Total cost
—
Partners
49 organisations in 14 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101081481

What the project is doing

In the project's own words, from its summary on CORDIS.

Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a group of parents and healthcare professionals in the Netherlands started working towards one national children’s cancer centre that could accelerate advances in treatment by centralizing all patient care and research in one building. Those efforts led to the creation of the Princess Máxima Centre for paediatric oncology: a unique centre that brings together all the highly complex care and research for children with cancer in the Netherlands.

This concentration and integration of specialized paediatric oncology reflects our mission: ‘To provide a cure for every child with cancer while maintaining an optimal quality of life’. Only with innovative research we will be able to improve survival and quality of life for children with cancer. Our research covers the entire spectrum: from fundamental research to expose genetic and molecular characteristics of tumour cells to clinical trials to test improved treatment options.

And from translational experiments to develop personalized therapy to psychosocial studies that monitor the wellbeing of the whole family. Collaborations within our center, between researchers and clinicians, but also partnerships with other institutes, nationally and internationally, are crucial to reach our goals. To contribute to this effort, the MAXIMA-BUTTERFLY programme will train the next generation of multi-disciplinary scientists in the field of paediatric oncology.

For a successful implementation and to achieve a radical change in the society, the work needs to be translated to the academic community, the industry, health policy makers, regulatory authorities, insurance companies, doctors, patients, patients advocates, and the general public. Therefore, a multidisciplinary research team of scientists based in the Princess Máxima Centre are applying for a Marie Skłodowska-Curie COFUND grant for 28 DCs.

Topics

Who is involved

OrganisationCityCountryRole
Prinses Maxima Centrum Voor Kinderoncologie BVUtrechtNetherlandsCoordinator
Institut Fuer Molekulare Biotechnologie GmbHWienAustriaAssociatedpartner
St. Anna Kinderkrebsforschung GmbHWienAustriaAssociatedpartner
Murdoch Children's Research InstituteMelbourneAustraliaAssociatedpartner
Katholieke Universiteit LeuvenLeuvenBelgiumAssociatedpartner
Universiteit GentGentBelgiumAssociatedpartner
F. Hoffmann-La Roche AGBaselSwitzerlandAssociatedpartner
Universitat ZurichZurichSwitzerlandAssociatedpartner
Fakultni Nemocnice Motol a HomolkaPraha 5CzechiaAssociatedpartner
Charles River Discovery Research Services Germany GmbHFreiburgGermanyAssociatedpartner
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyAssociatedpartner
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyAssociatedpartner
Klinikum Oldenburg gGmbHOldenburgGermanyAssociatedpartner
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainAssociatedpartner
Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos IiiMadridSpainAssociatedpartner
Universidad De NavarraPamplonaSpainAssociatedpartner
Innovative Therapies for Children with Cancer AssociationVillejuifFranceAssociatedpartner
Institut CurieParisFranceAssociatedpartner
TherapanaceaParisFranceAssociatedpartner
Xentech SASEvryFranceAssociatedpartner
Fondazione Human TechnopoleMilanoItalyAssociatedpartner
Scientific Directorate Research Unit for Multifactorial Disease Bambino Gesu Childrens HospitalRomeItalyAssociatedpartner
Academisch Ziekenhuis GroningenGroningenNetherlandsAssociatedpartner
Crown Bioscience Netherlands BVLeidenNetherlandsAssociatedpartner
Cyclomics BVAmsterdamNetherlandsAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsAssociatedpartner
Mimetas BVLeidenNetherlandsAssociatedpartner
Stichting Amsterdam UmcAmsterdamNetherlandsAssociatedpartner
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsAssociatedpartner
Stichting Hubrecht Organoid TechnologyUtrechtNetherlandsAssociatedpartner
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsAssociatedpartner
Universitair Medisch Centrum UtrechtUtrechtNetherlandsAssociatedpartner
Universiteit Utrecht Holding BVUtrechtNetherlandsAssociatedpartner
Vereniging Kinderkanker NederlandDe BiltNetherlandsAssociatedpartner
Xilis BVUtrechtNetherlandsAssociatedpartner
Region SkaneKristianstadSwedenAssociatedpartner
Narodny Ustav Detskych ChorobBratislavaSlovakiaAssociatedpartner
Astrazeneca UK LimitedCambridgeUnited KingdomAssociatedpartner
Great Ormond Street Hospital for Children Nhs Foundation TrustLondonUnited KingdomAssociatedpartner
Solving Kids Cancer UK LtdLondonUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
Regents of the University of MichiganAnn ArborUnited StatesAssociatedpartner
St. Jude Children's Research HospitalMemphisUnited StatesAssociatedpartner
The Regents of the University of CaliforniaOaklandUnited StatesAssociatedpartner
The Nemours FoundationWilmingtonUnited StatesAssociatedpartner
University of TennesseeMemphisUnited StatesAssociatedpartner
Virginia Commonwealth UniversityRichmond, VAUnited StatesAssociatedpartner
Whitehead Institute for Biomedical ResearchCambridgeUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI